ANI Pharmaceuticals Inc. insider trading
This tab shows only the shares insiders bought or sold on the open market in the last twelve months (Form 4 codes P and S). Grants, option exercises, shares held back for tax and gifts are left out on purpose, so what is left is insiders trading at the market price like anyone else.
In the last twelve months insiders at ANI Pharmaceuticals Inc. filed 48 open-market sales worth $15.1 million and 0 open-market purchases, on Form 4 with the SEC. The latest: Carey Stephen P., SVP & CFO, sold 2,850 shares at $73.00 on 29 September 2026, filed 30 September 2026.
| Traded | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 29 September 2026 | Carey Stephen P. | SVP & CFO | Sale | 2,850 | $73.00 | $208,050 | Form 4 |
| 15 September 2026 | Lalwani Nikhil | President & CEO | Sale | 5,400 | $71.00 | $383,400 | Form 4 |
| 14 September 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $70.79 | $35,395 | Form 4 |
| 11 September 2026 | Thoma Jeanne | Director | Sale | 1,000 | $71.53 | $71,530 | Form 4 |
| 31 August 2026 | Carey Stephen P. | SVP & CFO | Sale | 2,850 | $72.80 | $207,480 | Form 4 |
| 25 August 2026 | Lalwani Nikhil | President & CEO | Sale | 5,400 | $74.30 | $401,220 | Form 4 |
| 13 August 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $75.48 | $37,740 | Form 4 |
| 10 August 2026 | Gutwerg Ori | SVP, Generics | Sale | 3,162 | $77.00 | $243,474 | Form 4 |
| 29 July 2026 | Carey Stephen P. | SVP & CFO | Sale | 2,850 | $81.36 | $231,876 | Form 4 |
| 13 July 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $81.84 | $40,920 | Form 4 |
| 2 July 2026 | Carey Stephen P. | SVP & CFO | Sale | 3,313 | $86.00 | $284,918 | Form 4 |
| 29 June 2026 | Carey Stephen P. | SVP & CFO | Sale | 2,850 | $84.12 | $239,742 | Form 4 |
| 12 June 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $82.03 | $41,015 | Form 4 |
| 8 June 2026 | Haughey Thomas | Director | Sale | 2,000 | $80.88 | $161,760 | Form 4 |
| 5 June 2026 | Carey Stephen P. | SVP & CFO | Sale | 3,312 | $80.00 | $264,960 | Form 4 |
| 13 May 2026 | Walsh Patrick D | Director | Sale | 10,000 | $80.63 | $806,300 | Form 4 |
| 13 May 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $78.16 | $39,080 | Form 4 |
| 12 May 2026 | Rowland Thomas Andrew | SVP, HEAD - Established Brands | Sale | 459 | $79.21 | $36,357 | Form 4 |
| 12 May 2026 | Gutwerg Ori | SVP, Generics | Sale | 2,772 | $79.50 | $220,374 | Form 4 |
| 11 May 2026 | Walsh Patrick D | Director | Sale | 3,973 | $80.75 | $320,820 | Form 4 |
| 11 May 2026 | Lalwani Nikhil | President & CEO | Sale | 55,000 | $77.57 | $4.3 million | Form 4 |
| 13 April 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $77.95 | $38,975 | Form 4 |
| 13 March 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 3,162 | $71.64 | $226,526 | Form 4 |
| 13 March 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $72.62 | $36,310 | Form 4 |
| 11 March 2026 | Rowland Thomas Andrew | SVP, HEAD - Established Brands | Sale | 4,772 | $74.91 | $357,471 | Form 4 |
| 9 March 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 3,602 | $74.18 | $267,196 | Form 4 |
| 9 March 2026 | Davis Krista | SVP, Chief HR Officer | Sale | 5,087 | $74.13 | $377,099 | Form 4 |
| 6 March 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 2,121 | $74.22 | $157,421 | Form 4 |
| 6 March 2026 | Davis Krista | SVP, Chief HR Officer | Sale | 1,485 | $75.00 | $111,375 | Form 4 |
| 5 March 2026 | Carey Stephen P. | SVP & CFO | Sale | 3,312 | $75.42 | $249,791 | Form 4 |
| 5 March 2026 | Carey Stephen P. | SVP & CFO | Sale | 4,000 | $75.56 | $302,240 | Form 4 |
| 3 March 2026 | Gutwerg Ori | SVP, Generics | Sale | 2,060 | $76.50 | $157,590 | Form 4 |
| 2 March 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 417 | $74.00 | $30,858 | Form 4 |
| 3 March 2026 | Walsh Patrick D | Director | Sale | 6,000 | $74.23 | $445,380 | Form 4 |
| 20 February 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 5,323 | $78.02 | $415,300 | Form 4 |
| 20 February 2026 | Davis Krista | SVP, Chief HR Officer | Sale | 1,730 | $77.99 | $134,923 | Form 4 |
| 19 February 2026 | Davis Krista | SVP, Chief HR Officer | Sale | 2,084 | $77.53 | $161,573 | Form 4 |
| 13 February 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $76.80 | $38,400 | Form 4 |
| 12 February 2026 | Mutz Christopher | HEAD OF RARE Disease | Sale | 7,032 | $76.55 | $538,300 | Form 4 |
| 13 January 2026 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 500 | $84.33 | $42,165 | Form 4 |
| 18 December 2025 | Davis Krista | SVP, Chief HR Officer | Sale | 1,622 | $82.40 | $133,653 | Form 4 |
| 12 December 2025 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 400 | $82.32 | $32,928 | Form 4 |
| 5 December 2025 | Tannenbaum Renee P | Director | Sale | 1,800 | $81.15 | $146,070 | Form 4 |
| 13 November 2025 | Walsh Patrick D | Director | Sale | 8,643 | $86.88 | $750,904 | Form 4 |
| 13 November 2025 | Gassert Chad | SVP - CORP. DEV. & Strategy | Sale | 94 | $88.00 | $8,272 | Form 4 |
| 13 November 2025 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 400 | $87.27 | $34,908 | Form 4 |
| 12 November 2025 | Gassert Chad | SVP - CORP. DEV. & Strategy | Sale | 14,642 | $89.07 | $1.3 million | Form 4 |
| 13 October 2025 | Cook Meredith | SR. VP, General Counsel & SEC. | Sale | 400 | $90.09 | $36,036 | Form 4 |
A filing with several lines appears once per line.
Source
Form 4 filings on EDGAR for ANI Pharmaceuticals Inc.: the company's filing index.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.